JP2016520313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520313A5 JP2016520313A5 JP2016515304A JP2016515304A JP2016520313A5 JP 2016520313 A5 JP2016520313 A5 JP 2016520313A5 JP 2016515304 A JP2016515304 A JP 2016515304A JP 2016515304 A JP2016515304 A JP 2016515304A JP 2016520313 A5 JP2016520313 A5 JP 2016520313A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- acid sequence
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 208000024781 Immune Complex disease Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000004221 Multiple Trauma Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 238000007631 vascular surgery Methods 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 1
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 1
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 101000993321 Homo sapiens Complement C2 Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000005782 double-strand break Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 1
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13168941 | 2013-05-23 | ||
| EP13168941.6 | 2013-05-23 | ||
| PCT/NL2014/050327 WO2014189378A1 (en) | 2013-05-23 | 2014-05-22 | Binding molecules that bind human complement factor c2 and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019148550A Division JP7163254B2 (ja) | 2013-05-23 | 2019-08-13 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520313A JP2016520313A (ja) | 2016-07-14 |
| JP2016520313A5 true JP2016520313A5 (https=) | 2018-12-06 |
Family
ID=48485015
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515304A Pending JP2016520313A (ja) | 2013-05-23 | 2014-05-22 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
| JP2019148550A Active JP7163254B2 (ja) | 2013-05-23 | 2019-08-13 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
| JP2022167816A Active JP7414929B2 (ja) | 2013-05-23 | 2022-10-19 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019148550A Active JP7163254B2 (ja) | 2013-05-23 | 2019-08-13 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
| JP2022167816A Active JP7414929B2 (ja) | 2013-05-23 | 2022-10-19 | ヒト補体因子ｃ２に結合する結合分子、及び、その使用。 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9944717B2 (https=) |
| EP (2) | EP2999714B1 (https=) |
| JP (3) | JP2016520313A (https=) |
| CN (1) | CN105492461B (https=) |
| AU (1) | AU2014269193C1 (https=) |
| CA (1) | CA2913318C (https=) |
| DK (2) | DK3725803T3 (https=) |
| ES (2) | ES2904709T3 (https=) |
| HU (2) | HUE049769T2 (https=) |
| LT (2) | LT2999714T (https=) |
| MX (1) | MX366046B (https=) |
| PL (2) | PL3725803T3 (https=) |
| PT (2) | PT3725803T (https=) |
| WO (1) | WO2014189378A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| CN105492461B (zh) * | 2013-05-23 | 2019-11-26 | 布罗泰欧制药有限公司 | 结合人类补体因子c2的结合分子及其应用 |
| HUE073475T2 (hu) * | 2016-10-12 | 2026-01-28 | Bioverativ Usa Inc | C1s elleni antitestek és alkalmazási eljárásaik |
| WO2020121282A1 (en) * | 2018-12-13 | 2020-06-18 | Argenx Bvba | Antibodies to human complement factor c2b and methods of use |
| GB2584105B (en) | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| WO2021026609A1 (en) * | 2019-08-12 | 2021-02-18 | CSL Innovation Pty Ltd | Complement c2 binding proteins and uses thereof |
| AU2023210793A1 (en) * | 2022-01-29 | 2024-06-06 | Kira Pharmaceuticals (Suzhou) Ltd. | Anti-c2 antibodies and uses thereof |
| GB202407051D0 (en) | 2024-05-17 | 2024-07-03 | argenx BV | Methods of treating osteoarthritis pain |
| WO2025257157A1 (en) | 2024-06-10 | 2025-12-18 | argenx BV | Treatment or prevention of ischemia reperfusion injury in organ tranplantation |
| WO2025260123A1 (en) * | 2024-06-17 | 2025-12-26 | CSL Innovation Pty Ltd | Anti-c2 antibodies and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| AU2001249410A1 (en) | 2000-03-23 | 2001-10-03 | Tanox, Inc. | Anti-c2/c2a inhibitors of complement activation |
| CN105492461B (zh) | 2013-05-23 | 2019-11-26 | 布罗泰欧制药有限公司 | 结合人类补体因子c2的结合分子及其应用 |
-
2014
- 2014-05-22 CN CN201480042146.0A patent/CN105492461B/zh active Active
- 2014-05-22 EP EP14729463.1A patent/EP2999714B1/en active Active
- 2014-05-22 US US14/892,850 patent/US9944717B2/en active Active
- 2014-05-22 PL PL20165165T patent/PL3725803T3/pl unknown
- 2014-05-22 CA CA2913318A patent/CA2913318C/en active Active
- 2014-05-22 LT LTEP14729463.1T patent/LT2999714T/lt unknown
- 2014-05-22 ES ES20165165T patent/ES2904709T3/es active Active
- 2014-05-22 PL PL14729463T patent/PL2999714T3/pl unknown
- 2014-05-22 HU HUE14729463A patent/HUE049769T2/hu unknown
- 2014-05-22 PT PT201651650T patent/PT3725803T/pt unknown
- 2014-05-22 MX MX2015016120A patent/MX366046B/es active IP Right Grant
- 2014-05-22 DK DK20165165.0T patent/DK3725803T3/da active
- 2014-05-22 WO PCT/NL2014/050327 patent/WO2014189378A1/en not_active Ceased
- 2014-05-22 AU AU2014269193A patent/AU2014269193C1/en active Active
- 2014-05-22 ES ES14729463T patent/ES2784616T3/es active Active
- 2014-05-22 DK DK14729463.1T patent/DK2999714T3/da active
- 2014-05-22 EP EP20165165.0A patent/EP3725803B1/en active Active
- 2014-05-22 HU HUE20165165A patent/HUE057858T2/hu unknown
- 2014-05-22 LT LTEP20165165.0T patent/LT3725803T/lt unknown
- 2014-05-22 JP JP2016515304A patent/JP2016520313A/ja active Pending
- 2014-05-22 PT PT147294631T patent/PT2999714T/pt unknown
-
2018
- 2018-02-23 US US15/903,810 patent/US10717785B2/en active Active
-
2019
- 2019-08-13 JP JP2019148550A patent/JP7163254B2/ja active Active
-
2022
- 2022-10-19 JP JP2022167816A patent/JP7414929B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520313A5 (https=) | ||
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| ES2292682T3 (es) | Purificacion de anticuerpos mediante cromatografia de intercambio ionico. | |
| JP2019535763A5 (https=) | ||
| JP2014518883A5 (https=) | ||
| JP2018517431A5 (https=) | ||
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| RU2021129189A (ru) | Антитела против фактора свертывания xi | |
| JP2019022499A5 (https=) | ||
| JP2016529229A5 (https=) | ||
| JP2016523235A5 (https=) | ||
| JP2014533239A5 (https=) | ||
| WO2006116269A3 (en) | Antibodies to myostatin | |
| CY1111337T1 (el) | Βελτιωμενα επιλεκτικα πρωτοϊνιδιων αντισωματα και η χρηση αυτων | |
| WO2014114651A9 (en) | Tnf-alpha antigen-binding proteins | |
| IL275720B (en) | Use of molecules that bind semphorin-d4 for the treatment of neurodegenerative disorders | |
| JP2020007318A5 (https=) | ||
| JP2013538057A5 (https=) | ||
| JP2021502984A5 (https=) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| EP3261720A1 (en) | Antibodies to tau and uses thereof | |
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| MX2018000696A (es) | Anticuerpos humanizados anti-beta-amiloide piroglutamados. | |
| JP2017504321A5 (https=) | ||
| MX2021003867A (es) | Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado. |